Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 15/20 | 0.78 |
| ▸ | DHODH | Q02127 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823663 | 0.89 | CHRNA7 (0.68) | GRIK1DHODHRAB9AKDM4ENPC1 | |
| SCHEMBL5595227 | 0.88 | GRIK1 (0.74) | GRIK1DHODHRAB9AKDM4ENPC1 | |
| SCHEMBL7675947 | 0.85 | GRIK1 (0.74) | GRIK1RAB9AKDM4ENPC1MEN1 | |
| SCHEMBL5950332 | 0.85 | GRIK1 (0.78) | GRIK1DHODHRAB9AKDM4ENPC1 | |
| SCHEMBL16489012 | 0.84 | EGFR (0.66) | GRIK1DHODHMEN1KMT2AMAPT | |
| SCHEMBL7822988 | 0.83 | MEN1 (0.63) | GRIK1RAB9AKDM4ENPC1MEN1 | |
| SCHEMBL11983339 | 0.83 | DHODH (1.00) | GRIK1DHODHRAB9AKDM4ENPC1 | |
| SCHEMBL5594687 | 0.82 | KDM4E (0.68) | GRIK1DHODHRAB9AKDM4ENPC1 | |
| SCHEMBL4912702 | 0.82 | RAB9A (0.59) | GRIK1DHODHRAB9AKDM4ENPC1 | |
| SCHEMBL7554091 | 0.82 | GRIK1 (0.67) | GRIK1DHODHRAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | CXCL8, CCR8, IL1RN | GRIK1 3379/4885DHODH 2703/4885RAB9A 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.